76 related articles for article (PubMed ID: 18410593)
21. Soluble epoxide hydrolase in atherosclerosis.
Wang YX; Ulu A; Zhang LN; Hammock B
Curr Atheroscler Rep; 2010 May; 12(3):174-83. PubMed ID: 20425256
[TBL] [Abstract][Full Text] [Related]
22. mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators".
Nakanishi M; Gokhale V; Meuillet EJ; Rosenberg DW
Biochimie; 2010 Jun; 92(6):660-4. PubMed ID: 20159031
[TBL] [Abstract][Full Text] [Related]
23. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis.
Wang M; Zukas AM; Hui Y; Ricciotti E; Puré E; FitzGerald GA
Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14507-12. PubMed ID: 16973753
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular Consequences of Prostanoid I Receptor Deletion in Microsomal Prostaglandin E Synthase-1-Deficient Hyperlipidemic Mice.
Tang SY; Monslow J; R Grant G; Todd L; Pawelzik SC; Chen L; Lawson J; Puré E; FitzGerald GA
Circulation; 2016 Jul; 134(4):328-38. PubMed ID: 27440004
[TBL] [Abstract][Full Text] [Related]
25. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation.
Xu D; Rowland SE; Clark P; Giroux A; Côté B; Guiral S; Salem M; Ducharme Y; Friesen RW; Méthot N; Mancini J; Audoly L; Riendeau D
J Pharmacol Exp Ther; 2008 Sep; 326(3):754-63. PubMed ID: 18524979
[TBL] [Abstract][Full Text] [Related]
26. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.
Mbalaviele G; Pauley AM; Shaffer AF; Zweifel BS; Mathialagan S; Mnich SJ; Nemirovskiy OV; Carter J; Gierse JK; Wang JL; Vazquez ML; Moore WM; Masferrer JL
Biochem Pharmacol; 2010 May; 79(10):1445-54. PubMed ID: 20067770
[TBL] [Abstract][Full Text] [Related]
27. Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease.
Wang M; Song WL; Cheng Y; Fitzgerald GA
J Intern Med; 2008 May; 263(5):500-5. PubMed ID: 18410593
[TBL] [Abstract][Full Text] [Related]
28. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders.
Koeberle A; Werz O
Biochem Pharmacol; 2015 Nov; 98(1):1-15. PubMed ID: 26123522
[TBL] [Abstract][Full Text] [Related]
29. Characterization of microsomal prostaglandin E synthase 1 inhibitors.
Korotkova M; Jakobsson PJ
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):64-9. PubMed ID: 24138533
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of microsomal prostaglandin E2 synthase-1 enzyme as emerging anti-inflammatory candidates.
Bahia MS; Katare YK; Silakari O; Vyas B; Silakari P
Med Res Rev; 2014 Jul; 34(4):825-55. PubMed ID: 25019142
[TBL] [Abstract][Full Text] [Related]
31. PGE synthase inhibitors as an alternative to COX-2 inhibitors.
Jachak SM
Curr Opin Investig Drugs; 2007 May; 8(5):411-5. PubMed ID: 17520870
[TBL] [Abstract][Full Text] [Related]
32. Cardiovascular biology of microsomal prostaglandin E synthase-1.
Wang M; FitzGerald GA
Trends Cardiovasc Med; 2010 Aug; 20(6):189-95. PubMed ID: 22137640
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
